Keywords:
sildenafil citrate
oligohydramnios
pregnancy
amniotic fluid index (AFI)
intrauterine environment
gestation

  • Abstract

    This comprehensive review examines the potential role of sildenafil citrate in ameliorating oligohydramnios in pregnant women, focusing on its impact on amniotic fluid indices. Oligohydramnios, characterised by insufficient amniotic fluid, pose significant risks to fetal and maternal health. This review begins by elucidating the definition of oligohydramnios and its implications in pregnancy, emphasising the critical role of amniotic fluid in foetal development. The rationale for studying sildenafil citrate lies in its vasodilatory properties and potential to improve uteroplacental blood flow, thereby influencing amniotic fluid dynamics. The importance of amniotic fluid indices, particularly the amniotic fluid index (AFI), is discussed, highlighting their relevance as critical indicators of fetal well-being. This review synthesises evidence from experimental studies, both animal and human, exploring the effects of sildenafil citrate on amniotic fluid levels. Safety considerations, maternal and fetal outcomes, and the limitations of existing research are also addressed. The conclusions summarise vital findings, discuss implications for clinical practice, and emphasise the need for further research to establish the safety and efficacy of sildenafil citrate in managing oligohydramnios. This review contributes valuable insights for healthcare professionals, researchers, and policymakers seeking evidence-based approaches to enhance pregnancy outcomes in cases of oligohydramnios.

  • References

    1. Bakhsh, H., Alenizy, H., Alenazi, S., Alnasser, S., Alanazi, N., Alsowinea, M., Alharbi, L., & Alfaifi, B. (2021). Amniotic fluid disorders and the effects on prenatal outcome: A retrospective cohort study. BMC Pregnancy and Childbirth, 21, 75. https://doi.org/10.1186/s12884-021-03549-3
    2. Choudhary, R., Desai, K., Parekh, H., & Ganla, K. (2016). Sildenafil citrate for the management of fetal growth restriction and oligohydramnios. International Journal of Women’s Health, 8, 367–372. https://doi.org/10.2147/IJWH.S108370
    3. Dastjerdi, M. V., Hosseini, S., & Bayani, L. (2012). Sildenafil citrate and uteroplacental perfusion in fetal growth restriction. Journal of Research in Medical Sciences : The Official Journal of Isfahan University of Medical Sciences, 17(7), 632–636.
    4. De Bie, F. R., Basurto, D., Kumar, S., Deprest, J., & Russo, F. M. (2022). Sildenafil during the 2nd and 3rd Trimester of Pregnancy: Trials and Tribulations. International Journal of Environmental Research and Public Health, 19(18), 11207. https://doi.org/10.3390/ijerph191811207
    5. Debbink, M. P., Son, S. L., Woodward, P. J., & Kennedy, A. M. (2021). Sonographic Assessment of Fetal Growth Abnormalities. RadioGraphics, 41(1), 268–288. https://doi.org/10.1148/rg.2021200081
    6. Ezuruike, U., Blenkinsop, A., Pansari, A., & Abduljalil, K. (2022). Quantification of Fetal Renal Function Using Fetal Urine Production Rate and Its Reflection on the Amniotic and Fetal Creatinine Levels During Pregnancy. Frontiers in Pediatrics, 10, 841495. https://doi.org/10.3389/fped.2022.841495
    7. Ferreira, R. D. da S., Negrini, R., Bernardo, W. M., Simões, R., & Piato, S. (2019). The effects of sildenafil in maternal and fetal outcomes in pregnancy: A systematic review and meta-analysis. PLoS ONE, 14(7), e0219732. https://doi.org/10.1371/journal.pone.0219732
    8. Figueroa, L., McClure, E. M., Swanson, J., Nathan, R., Garces, A. L., Moore, J. L., Krebs, N. F., Hambidge, K. M., Bauserman, M., Lokangaka, A., Tshefu, A., Mirza, W., Saleem, S., Naqvi, F., Carlo, W. A., Chomba, E., Liechty, E. A., Esamai, F., Swanson, D., … Goldenberg, R. L. (2020). Oligohydramnios: A prospective study of fetal, neonatal and maternal outcomes in low-middle income countries. Reproductive Health, 17, 19. https://doi.org/10.1186/s12978-020-0854-y
    9. Fitzsimmons, E. D., & Bajaj, T. (2024). Embryology, Amniotic Fluid. In StatPearls. StatPearls Publishing. http://www.ncbi.nlm.nih.gov/books/NBK541089/
    10. Ghofrani, H. A., Osterloh, I. H., & Grimminger, F. (2006). Sildenafil: From angina to erectile dysfunction to pulmonary hypertension and beyond. Nature Reviews. Drug Discovery, 5(8), 689–702. https://doi.org/10.1038/nrd2030
    11. Gillis, E. E., Mooney, J. N., Garrett, M. R., Granger, J. P., & Sasser, J. M. (2016). Sildenafil treatment ameliorates the maternal syndrome of preeclampsia and rescues fetal growth in the Dahl Salt Sensitive rat. Hypertension, 67(3), 647–653. https://doi.org/10.1161/HYPERTENSIONAHA.115.06071
    12. Giuliano, F., Jackson, G., Montorsi, F., Martin-Morales, A., & Raillard, P. (2010). Safety of sildenafil citrate: Review of 67 double-blind placebo-controlled trials and the postmarketing safety database. International Journal of Clinical Practice, 64(2), 240–255. https://doi.org/10.1111/j.1742-1241.2009.02254.x
    13. Gizzo, S., Noventa, M., Vitagliano, A., Dall’Asta, A., D’Antona, D., Aldrich, C. J., Quaranta, M., Frusca, T., & Patrelli, T. S. (2015). An Update on Maternal Hydration Strategies for Amniotic Fluid Improvement in Isolated Oligohydramnios and Normohydramnios: Evidence from a Systematic Review of Literature and Meta-Analysis. PLoS ONE, 10(12), e0144334. https://doi.org/10.1371/journal.pone.0144334
    14. Hale, S. A., Jones, C. W., Osol, G., Schonberg, A., Badger, G. J., & Bernstein, I. M. (2010). Sildenafil Increases Uterine Blood Flow in Nonpregnant Nulliparous Women. Reproductive Sciences (Thousand Oaks, Calif.), 17(4), 358–365. https://doi.org/10.1177/1933719109354648
    15. Hatzimouratidis, K. (2006). Sildenafil in the treatment of erectile dysfunction: An overview of the clinical evidence. Clinical Interventions in Aging, 1(4), 403–414.
    16. Hl, P., Kms, R., Dnb, S., Venkatesh, & Kanth, L. (2016). Study of effect of sildenafil citrate in pregnant women with intrauterine growth restriction/oligohydramnios. International Journal of Reproduction, Contraception, Obstetrics and Gynecology, 5(9), 3094–3097. https://doi.org/10.18203/2320-1770.ijrcog20162992
    17. Huang, S. A., & Lie, J. D. (2013). Phosphodiesterase-5 (PDE5) Inhibitors In the Management of Erectile Dysfunction. Pharmacy and Therapeutics, 38(7), 407–419.
    18. Keilman, C., & Shanks, A. L. (2024). Oligohydramnios. In StatPearls. StatPearls Publishing. http://www.ncbi.nlm.nih.gov/books/NBK562326/
    19. Khan, I. U., Aslam, N., Anis, F. M., Mirza, S., AlOwayed, A., Aljuaid, R. M., & Bakr, R. M. (2022). Amniotic Fluid Classification and Artificial Intelligence: Challenges and Opportunities. Sensors, 22(12), Article 12. https://doi.org/10.3390/s22124570
    20. McMurray, J. G., Feldman, R. A., Auerbach, S. M., DeRiesthal, H., & Wilson, N. (2007). Long-term safety and effectiveness of sildenafil citrate in men with erectile dysfunction. Therapeutics and Clinical Risk Management, 3(6), 975–981.
    21. Nasrolahi, S., Talebi-Ghane, E., & Torkashvand, L. (2023). The Effect of Sildenafil Citrate on Improving Amniotic Fluid Index in Pregnant Women with Oligohydramnios and Borderline Oligohydramnios: A Randomized Controlled Trial. Journal of Kermanshah University of Medical Sciences, 27(2), Article 2. https://doi.org/10.5812/jkums-135045
    22. Opichka, M. A., Rappelt, M. W., Gutterman, D. D., Grobe, J. L., & McIntosh, J. J. (2021). Vascular Dysfunction in Preeclampsia. Cells, 10(11), 3055. https://doi.org/10.3390/cells10113055
    23. Panda, S., Das, A., & Md Nowroz, H. (2014). Sildenafil Citrate in Fetal Growth Restriction. Journal of Reproduction & Infertility, 15(3), 168–169.
    24. Pels, A., Derks, J., Elvan-Taspinar, A., van Drongelen, J., de Boer, M., Duvekot, H., van Laar, J., van Eyck, J., Al-Nasiry, S., Sueters, M., Post, M., Onland, W., van Wassenaer-Leemhuis, A., Naaktgeboren, C., Jakobsen, J. C., Gluud, C., Duijnhoven, R. G., Lely, T., Gordijn, S., & Ganzevoort, W. (2020). Maternal Sildenafil vs Placebo in Pregnant Women With Severe Early-Onset Fetal Growth Restriction. JAMA Network Open, 3(6), e205323. https://doi.org/10.1001/jamanetworkopen.2020.5323
    25. Pels, A., Kenny, L. C., Alfirevic, Z., Baker, P. N., von Dadelszen, P., Gluud, C., Kariya, C. T., Mol, B. W., Papageorghiou, A. T., van Wassenaer-Leemhuis, A. G., Ganzevoort, W., & Groom, K. M. (2017). STRIDER (Sildenafil TheRapy in dismal prognosis early onset fetal growth restriction): An international consortium of randomised placebo-controlled trials. BMC Pregnancy and Childbirth, 17, 440. https://doi.org/10.1186/s12884-017-1594-z
    26. Rakhanova, Y., Almawi, W. Y., Aimagambetova, G., & Riethmacher, D. (2023). The effects of sildenafil citrate on intrauterine growth restriction: A systematic review and meta-analysis. BMC Pregnancy and Childbirth, 23, 409. https://doi.org/10.1186/s12884-023-05747-7
    27. Sharp, A., Cornforth, C., Jackson, R., Harrold, J., Turner, M. A., Kenny, L. C., Baker, P. N., Johnstone, E. D., Khalil, A., von Dadelszen, P., Papageorghiou, A. T., Alfirevic, Z., Agarwal, U., Willis, E., Mammarella, S., Masson, G., Aquilina, J., Greco, E., Higgins, S., … Bugg, G. (2018). Maternal sildenafil for severe fetal growth restriction (STRIDER): A multicentre, randomised, placebo-controlled, double-blind trial. The Lancet Child & Adolescent Health, 2(2), 93–102. https://doi.org/10.1016/S2352-4642(17)30173-6
    28. Terstappen, F., Spradley, F. T., Bakrania, B. A., Clarke, S. M., Joles, J. A., Paauw, N. D., Garrett, M. R., Lely, A. T., & Sasser, J. M. (2019). Prenatal sildenafil therapy improves cardiovascular function in fetal growth restricted offspring of Dahl Salt-Sensitive rats. Hypertension (Dallas, Tex. : 1979), 73(5), 1120–1127. https://doi.org/10.1161/HYPERTENSIONAHA.118.12454
    29. Turko, I. V., Ballard, S. A., Francis, S. H., & Corbin, J. D. (1999). Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (Type 5) by sildenafil and related compounds. Molecular Pharmacology, 56(1), 124–130. https://doi.org/10.1124/mol.56.1.124
    30. Twesigomwe, G., Migisha, R., Agaba, D. C., Owaraganise, A., Aheisibwe, H., Tibaijuka, L., Abesiga, L., Ngonzi, J., & Tornes, Y. F. (2022). Prevalence and associated factors of oligohydramnios in pregnancies beyond 36 weeks of gestation at a tertiary hospital in southwestern Uganda. BMC Pregnancy and Childbirth, 22, 610. https://doi.org/10.1186/s12884-022-04939-x
    31. Vahid Dastjerdi, M., Ghahghaei-Nezamabadi, A., Tehranian, A., & Mesgaran, M. (2022). The Effect of Sildenafil on Pregnancy Outcomes in Pregnant Women With Idiopathic Borderline Oligohydramnios: A Randomized Controlled Trial. Journal of Family & Reproductive Health, 16(2), 124–131. https://doi.org/10.18502/jfrh.v16i2.9482
    32. Vardi, Y., Klein, L., Nassar, S., Sprecher, E., & Gruenwald, I. (2002). Effects of sildenafil citrate (viagra) on blood pressure in normotensive and hypertensive men. Urology, 59(5), 747–752. https://doi.org/10.1016/s0090-4295(02)01510-8
    33. Zhang, X., & Huangfu, Z. (2022). Management of pregnant patients with pulmonary arterial hypertension. Frontiers in Cardiovascular Medicine, 9, 1029057. https://doi.org/10.3389/fcvm.2022.1029057
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright (c) 2024 The Authors

How to cite

Verma, S., & Singh, A. L. (2024). Role of sildenafil citrate in improving amniotic fluid indices in pregnant women with oligohydramnios: A comprehensive review. Multidisciplinary Reviews, 7(12), 2024294. https://doi.org/10.31893/multirev.2024294
Crossref
Scopus
Google Scholar
Europe PMC
  • Article viewed - 1157
  • PDF downloaded - 596